×
About 529,608 results

Pandemic Delayed Treatment in Patients With CTCL, Study Finds
https://www.medscape.com/viewarticle/984982

Dec 5th, 2022 - The early stages of the COVID-19 pandemic caused an average treatment delay of 3.2 months for 53% of patients with cutaneous T-cell lymphoma (CTCL), results from a retrospective study of nine international centers showed. However, among patients with CTCL diagnosed with COVID-19 during that time, no cases were acquired from outpatient visits. "Delays in therapy for patients with cutaneous lymph...

Infant BCG Vaccine Protects Only Those Under Age 5 Years
https://www.medscape.com/viewarticle/984995

Dec 5th, 2022 - Bacillus Calmette-Guérin (BCG) vaccines are given to more than 100 million children every year, but there is considerable debate regarding the effectiveness of BCG vaccination in preventing tuberculosis and death, particularly among older children and adults. The most extensive study ever conducted on the efficacy of the BCG vaccine for protection against tuberculosis, stratified by age and his...

Physicians React: On Access to Quality, Affordable Healthcare 
https://www.medscape.com/viewarticle/984985

Dec 5th, 2022 - Healthcare access is not an issue only for patients. In a recent Medscape report, more than a third of doctors surveyed said access to quality, affordable healthcare had affected them or their families. "Access affects even the highest earnings," noted one survey respondent, an ob/gyn. And about half of respondents in the Physicians Rate Healthcare Access Report: Ongoing Problem for Patients ch...

Higher BMI May Dampen Steroid Response in Eosinophilic Esophagitis
https://www.medscape.com/viewarticle/984983

Dec 5th, 2022 - New research suggests that body mass index (BMI) may influence response to topical corticosteroid (tCS) therapy for eosinophilic esophagitis (EoE). The higher the patient's BMI level, the lower the individual's response to tCS therapy from a symptomatic, endoscopic, and histologic perspective, researchers observed in a retrospective study. Because there are few clinical predictors of response t...

ASH 2022: New Clinical Data Challenge Long-held Assumptions
https://www.medscape.com/viewarticle/984997

Dec 5th, 2022 - NEW ORLEANS — In addition to news on the latest in clinical care and drug development, some eyebrow-raising findings that challenge long-held but untested assumptions are promised from the annual meeting of the American Society of Hematology. The conference starts in New Orleans on Saturday, but a sample of what is to come was given last week in a preview media briefing, moderated by Mikkael A....

United States to End Mpox Emergency Declaration
https://www.medscape.com/viewarticle/984948

Dec 5th, 2022 - (Reuters) -Mpox is expected to no longer be considered a public health emergency in the United States from Feb. 1, 2023, the U.S. health department said on Friday. The months-long declaration was meant to tackle the largest-ever outbreak of cases in the country. The move signals that the crisis, which led to a spate of cases mostly among men who have sex with men, has come under control and wou...

Volume 28, Number 12-December 2022
https://tools.cdc.gov/medialibrary/index.aspx#/media/id/732831

Table of Contents for Volume 28, Number 12-December 2022

Research Letter - Severe Human Case of Zoonotic Infection with Swine-Origin Influenza A Virus, Denmark, 2021
https://tools.cdc.gov/medialibrary/index.aspx#/media/id/732834

Research Letter — Severe Human Case of Zoonotic Infection with Swine-Origin Influenza A Virus, Denmark, 2021

Research Letter - Bombali Ebolavirus in Mops condylurus Bats (Molossidae), Mozambique
https://tools.cdc.gov/medialibrary/index.aspx#/media/id/732833

Research Letter — Bombali Ebolavirus in Mops condylurus Bats (Molossidae), Mozambique

Research - Association between Conflict and Cholera in Nigeria and the Democratic Republic of the Congo
https://tools.cdc.gov/medialibrary/index.aspx#/media/id/732832

Research — Association between Conflict and Cholera in Nigeria and the Democratic Republic of the Congo

Synopsis - Clinical and Epidemiologic Characteristics and Therapeutic Management of Patients with Vibrio Infections, Bay of Biscay, France, 2001-2019
https://tools.cdc.gov/medialibrary/index.aspx#/media/id/732871

Acute vibriosis led to serious adverse events in more than one third of patients with underlying conditions.

Research - Acinetobacter baumannii among Patients Receiving Glucocorticoid Aerosol Therapy during Invasive Mechanical Ventilation, China
https://tools.cdc.gov/medialibrary/index.aspx#/media/id/732835

Aerosolized glucocorticoid treatment was independently associated with bacterial isolation in these patients.

Foodborne Diseases
https://tools.cdc.gov/medialibrary/index.aspx#/media/id/298168

Let's eat! But this holiday season, let's eat safely. Don't let foodborne illness ruin your holiday plans.

Another Approval Bites the Dust; Booze-Cancer Link Off Radar; Lung Ca Surveillance
https://www.medpagetoday.com/hematologyoncology/othercancers/102029

Dec 2nd, 2022 - Roche/Genentech will voluntarily withdraw accelerated approval of atezolizumab (Tecentriq) for advanced bladder cancer. The move follows the failure of a phase III trial to show a benefit in overall survival. Cryotherapy proved more effective than thermal ablation of small renal tumors, according to a retrospective comparison of the two strategies. (Journal of Urology) A survey of 3,865 U.S. ad...

Brain Iron Chelation Linked With Worse Outcomes in Early Parkinson's
https://www.medpagetoday.com/neurology/parkinsonsdisease/102035

Dec 2nd, 2022 - Brain iron chelation with deferiprone was associated with worse parkinsonism symptoms and adverse events in early Parkinson's disease, the FAIRPARK-II trial showed. From baseline to week 36, mean total scores on the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) worsened more with deferiprone than placebo, reported David Devos, MD, PhD, of Université Lille in Fra...

Cardiovascular Risk Marker Improved With Common Rheumatoid Arthritis Drugs
https://www.medpagetoday.com/rheumatology/generalrheumatology/102023

Dec 2nd, 2022 - Rheumatoid arthritis patients treated with medications targeting the tumor necrosis factor (TNF) pathway or with standard disease-modifying anti-rheumatic drugs (DMARDs) showed substantial reductions in arterial inflammation, a key predictor of future cardiovascular disease, a randomized trial indicated. After 24 weeks of treatment with a TNF inhibitor or with a three-DMARD combination regimen,...

New IDH1 Inhibitor Wins FDA Approval for Acute Myeloid Leukemia
https://www.medpagetoday.com/hematologyoncology/leukemia/102019

Dec 2nd, 2022 - The FDA approved the IDH1 inhibitor olutasidenib (Rezlidhia) for relapsed or refractory acute myeloid leukemia (AML). The approved indication stipulates use of olutasidenib in relapsed/refractory AML associated with an IDH1 mutation. The FDA also approved the Abbott RealTime IDH1 Assay as a companion diagnostic to select patients for olutasidenib. "Rezlidhia is a novel, non-intensive monotherap...

Roivant, Pfizer Launch Unit to Develop Inflammatory Disease Drug
https://www.medscape.com/viewarticle/984837

Dec 2nd, 2022 - (Reuters) -Roivant Sciences and Pfizer Inc on Thursday announced the launch of a unit to develop RVT-3101, the drugmakers' treatment for an inflammatory bowel disease. The drug's efficacy as a treatment for ulcerative colitis is currently being assessed in a mid-stage study. Under the terms, biotech firm Roivant will be responsible for funding the development and will retain commercialization r...

FDA Declines to Approve Y-mAbs's Pediatric Cancer Drug
https://www.medscape.com/viewarticle/984894

Dec 2nd, 2022 - (Reuters) - The U.S. health regulator on Thursday declined to approve a treatment from Y-mAbs Therapeutics for a rare form of nerve cancer in pediatric patients, dragging the company's shares down 16% in extended trading. Y-mAbs said it is assessing the implications of the Food and Drug Administration's complete response letter (CRL) and the company's plans for the drug's development program. T...

High Drug Costs Exclude Most Neurology Patients From Cutting-Edge Treatment
https://www.medscape.com/viewarticle/984953

Dec 2nd, 2022 - Because of high out-of-pocket costs of new-to-market neurologic drugs that are of similar benefit as older agents, only a small percentage of patients with neurologic disorders have access to these cutting-edge medications, new research shows. "Our study of people with neurologic conditions found fewer than 20% were being treated with new medications," study author Brian C. Callaghan, MD, with ...